Jared Baeten, MD, PhD

The combination of the antiviral agents islatravir and lenacapavir demonstrates both efficacy and safety, leading to advancement into Phase 3 trials.

GS-1720 could offer a weekly dosing option for individuals living with HIV, supported by a good safety profile with no serious adverse events, which has led to the initiation of a Phase 2 study.

The Gilead capsid inhibitor has been shown to have less adverse events compared to another PrEP, and the company plans to begin regulatory filings for approval before the end of this year.